DC Chemicals Limited
China
Product Name: Zapnometinib
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

303175-44-2

303175-44-2 structure

Name: Zapnometinib
Chemical Name: 2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid
CAS Number: 303175-44-2
Molecular Formula: C₁₃H₇ClF₂INO₂
Molecular Weight: 409.55
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2019-01-01 21:57:53
Modify Date: 2024-01-11 07:41:57
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities[1][2][3].

Name	2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid
Synonyms	2,8-dimercapto-6-hydroxypurine hydrate,1gr

Description	Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities[1][2][3].
Related Catalog	Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> MEK Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
Target	MEK:5.7 nM (IC50)
In Vitro	Zapnometinib (0.1 nM-1 μM) inhibits MEK, with IC50s of 30.96 nM, 357 nM, and 15 nM in cell free kinase assay, A549, MDCK cells and human PBMCs[1]. Zapnometinib (100 μM; 4 h) inhibits the Ionomycin (PMA/I)-induced phosphorylation of ERK1/2 in human PBMCs[1]. Zapnometinib (1-100 μM) reduces the viral titers of the IV H1N1pdm09, H3N2[1]. Western Blot Analysis[1] Cell Line: human PBMCs Concentration: 100 μM Incubation Time: 4 h Result: Inhibited the Ionomycin (PMA/I)-increased pERK1/2.
In Vivo	Zapnometinib (8.4-75 mg/kg/day; three times a day p.o.) reduces the lung virus titers and enhances survival of mice after lethal H1N1pdm09 infection[1]. Zapnometinib (150 mg/kg) exhibits AUC values of 860.02 and 1953.68 μg•h/mL in mice by i.v. or oral route, respectively[1]. Animal Model: Female C57BL/6 mice (8 weeks; 21-24 g) were infected with H1N1pdm09[1] Dosage: 8.4, 25, 75 mg/kg/day (2.8, 8.4, 25 mg/kg) Administration: P.o. three times a day Result: Significantly reduced the virus titer at the dose of either 75 mg/kg/day or 25 mg/kg/day.
References	[1]. Laure M, et, al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res. 2020 Jun;178:104806. [2]. Hamza H, et, al. Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Front Microbiol. 2021 Feb 12;12:611958. [3]. Bruchhagen C, et, al. Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound. Sci Rep. 2018 Jun 14;8(1):9114.

Molecular Formula	C₁₃H₇ClF₂INO₂
Molecular Weight	409.55
Exact Mass	408.91800
PSA	49.33000
LogP	4.73760

42016-93-3

61079-72-9

~90%

303175-44-2

Literature: Davis, Edward M.; Nanninga, Thomas N.; Tjiong, Howie I.; Winkle, Derick D. Organic Process Research and Development, 2005 , vol. 9, # 6 p. 843 - 846

Precursor 2
42016-93-3 61079-72-9
DownStream 0

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4